Microneedling for hair loss is an increasingly popular procedure, but does it actually work? Microneedling — also called collagen induction therapy — uses fine needles to create controlled micro-injuries in the scalp, triggering growth factors that may stimulate dormant hair follicles. Originally developed for skin rejuvenation, it is now being explored as a treatment for androgenetic alopecia and alopecia areata, often alongside topical therapies such as minoxidil. This article examines the clinical evidence, who may be suitable, potential risks, and how to access treatment safely in the UK.

What Is Microneedling and How Is It Used for Hair Loss?

Microneedling uses fine needles to create micro-injuries in the scalp, stimulating growth factors that may promote hair follicle activity and transition follicles from the resting phase back into active growth.

Microneedling — also known as collagen induction therapy or percutaneous collagen induction — is a minimally invasive procedure that uses a device studded with fine needles to create controlled micro-injuries in the skin. Originally developed for facial rejuvenation and scar treatment, it has gained increasing attention as a potential treatment for certain types of hair loss, particularly androgenetic alopecia (pattern hair loss) and alopecia areata.

Not sure if this is normal? Chat with one of our pharmacists →

When applied to the scalp, the needles puncture the superficial layers of skin, triggering a wound-healing response. This process is thought to stimulate the release of growth factors, including platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), which may promote hair follicle activity and encourage the transition of follicles from the resting (telogen) phase back into the active growth (anagen) phase. These mechanisms are supported by mechanistic research into wound-induced follicle activity, though the precise pathways remain an area of ongoing study.

Microneedling for hair loss is typically performed using one of two devices:

• Dermarollers — handheld rollers with a drum covered in fine needles, used at home or in clinic

• Automated dermapens — motorised devices offering more precise needle depth control, generally used by trained practitioners

Needle depth and treatment frequency vary across clinical studies and should be individualised by a trained practitioner; published protocols have used needle depths of approximately 0.5 mm to 1.5 mm and session intervals ranging from weekly to every two to four weeks. In clinical settings, microneedling is frequently combined with topical treatments such as minoxidil or platelet-rich plasma (PRP) to potentially enhance absorption and efficacy. A course of treatment typically lasts several months before results can be meaningfully assessed.

Infection control and home use: If using a home dermaroller, it is essential to use single-use sterile needle cartridges where possible, never share devices with others, and follow the manufacturer's cleaning instructions for any reusable components. Topical agents such as minoxidil should generally be avoided for approximately 24 hours before and after needling unless a clinician advises otherwise, as disruption of the skin barrier may increase irritation and the risk of systemic absorption.

What Does the Evidence Say About Microneedling for Hair Loss?

Evidence is promising but not yet conclusive; randomised controlled trials support microneedling combined with minoxidil for androgenetic alopecia, though no large-scale long-term trials have established it as a standalone treatment.

The evidence base for microneedling as a hair loss treatment is growing, though it remains relatively limited in scale and quality. Most published studies are small, short-term, and use heterogeneous protocols, making it difficult to draw definitive conclusions. That said, several randomised controlled trials have produced encouraging results, particularly for androgenetic alopecia.

A frequently cited randomised controlled trial published in the Journal of Cutaneous and Aesthetic Surgery (Dhurat et al., 2013) compared microneedling combined with minoxidil against minoxidil alone in men with androgenetic alopecia. The microneedling group demonstrated significantly greater hair count improvement at 12 weeks, suggesting a potential synergistic effect. Subsequent systematic reviews and meta-analyses published between 2021 and 2023 have broadly supported this finding, reporting pooled improvements in hair count and density when microneedling is used as an adjunct to topical therapy, though heterogeneity between studies remains considerable and effect sizes vary.

For alopecia areata — an autoimmune condition causing patchy hair loss — evidence is more preliminary. Some small studies suggest microneedling may help stimulate regrowth, possibly by modulating local immune responses, though this mechanism is not fully understood and results have been inconsistent.

It is important to note that:

• No large-scale, long-term randomised controlled trials have yet established microneedling as a standalone, evidence-based treatment for hair loss

• Long-term data are limited: durability of response beyond six to twelve months is uncertain, and maintenance treatments may be required

• NICE has not issued specific guidance on microneedling for hair loss

• Microneedling devices are regulated as medical devices in the UK when they are intended and marketed for a medical purpose; however, some home-use or cosmetic-use devices may fall under consumer product safety regulations rather than medical device regulations, depending on the claims made — the regulatory position can be complex

Overall, current evidence is promising but not yet conclusive. Microneedling appears most effective when used as part of a combined treatment approach rather than as a sole intervention.

Who May Be Suitable for Microneedling as a Hair Loss Treatment?

Microneedling may suit individuals with androgenetic alopecia or stable alopecia areata who have not responded adequately to first-line treatments, but is contraindicated in active scalp infections, scarring alopecia, and several other conditions.

Microneedling is not appropriate for everyone experiencing hair loss, and a thorough assessment by a qualified healthcare professional or dermatologist is essential before beginning treatment. Suitability depends on the underlying cause of hair loss, overall scalp health, and individual medical history.

Those who may be considered suitable include:

• Individuals with androgenetic alopecia (male or female pattern hair loss) who have not achieved satisfactory results with first-line treatments such as minoxidil or finasteride

• People with alopecia areata in stable, non-extensive disease — though this should be assessed by a dermatologist, as standard first-line therapies (such as topical or intralesional corticosteroids) should be considered first under specialist guidance

• Those seeking to enhance the efficacy of topical treatments such as minoxidil, where microneedling may improve absorption

Microneedling is generally not recommended for individuals who:

• Have active scalp infections, including bacterial or fungal conditions (tinea capitis requires antifungal treatment and is not an indication for microneedling)

• Are experiencing active inflammatory scalp conditions such as seborrhoeic dermatitis, psoriasis, or lichen planus in the treatment area — these conditions carry a risk of Koebnerisation (triggering new lesions at sites of skin injury)

• Have a history of keloid scarring, as microneedling may exacerbate this tendency

• Are taking anticoagulant medications or have bleeding disorders

• Are pregnant or breastfeeding, as safety data in these groups is insufficient

• Have scalp malignancies or a history of skin cancer in the treatment area

• Have used oral isotretinoin recently (typically within the preceding six months), as wound healing may be impaired

Microneedling is not indicated for telogen effluvium or trichotillomania, and is unlikely to be beneficial in cases of scarring alopecia (such as lichen planopilaris or frontal fibrosing alopecia), where hair follicles have been permanently destroyed.

Red flags and when to seek urgent or specialist assessment: Individuals should be referred promptly to NHS dermatology if there is:

• Suspected scarring alopecia (erythema, scaling, pain, pustules, or progressive hair loss with follicular loss)

• Suspected tinea capitis, particularly in children (scaling, broken hairs, lymphadenopathy)

• Diagnostic uncertainty about the cause of hair loss

• Rapid or extensive progression

• Significant psychosocial distress

In all cases, establishing the correct diagnosis before any treatment is considered is essential. The NHS hair loss page and British Association of Dermatologists (BAD) patient information leaflets provide useful guidance on when to seek medical advice.

Possible Risks and Side Effects to Be Aware Of

Common side effects include temporary redness, tenderness, and pinpoint bleeding; more significant risks include infection, post-inflammatory hyperpigmentation, Koebnerisation, and enhanced absorption of topical agents applied post-treatment.

Experiencing these side effects? Our pharmacists can help you navigate them →

Microneedling is generally considered a low-risk procedure when performed correctly by a trained practitioner using appropriate equipment. However, as with any intervention that breaches the skin barrier, there are potential risks and side effects that patients should be fully informed about prior to treatment.

Common, short-term side effects following scalp microneedling include:

• Redness and mild swelling of the treated area, typically resolving within 24–48 hours

• Tenderness or sensitivity at the treatment site

• Pinpoint bleeding during the procedure, which is expected and usually minimal

• Temporary flaking or dryness of the scalp in the days following treatment

• Temporary increased shedding in the weeks following treatment, which may occur as part of the follicular response

Less common but more significant risks include:

• Infection — if equipment is not properly sterilised or aftercare instructions are not followed, bacteria can enter through the micro-channels created in the skin

• Post-inflammatory hyperpigmentation — more likely in individuals with darker skin tones

• Allergic reactions or irritation — particularly if topical agents such as minoxidil or PRP are applied immediately after needling, as enhanced skin penetration may increase the risk of systemic absorption or local reactions. For this reason, minoxidil and other topical irritants should generally be avoided for approximately 24 hours before and after treatment unless a clinician advises otherwise

• Koebnerisation — exacerbation or new lesions of inflammatory scalp conditions (such as psoriasis or lichen planus) at the site of needling

• Scarring — rare but possible, particularly with excessively deep needling or in those predisposed to abnormal wound healing

Aftercare guidance:

• Cleanse the scalp gently with a mild, non-irritating product

• Avoid minoxidil, retinoids, and other active topical agents for approximately 24 hours post-treatment

• Avoid swimming, saunas, and excessive heat until the scalp has healed

• Apply sun protection to any exposed areas

Home use: Patients using dermarollers at home should use single-use sterile needle cartridges, never share devices, and follow the manufacturer's cleaning instructions for any reusable components. Home use carries a higher risk of improper technique and inadequate sterilisation, and patients should seek professional guidance before self-treating.

Patients should contact their GP or treating practitioner promptly if they notice signs of infection (increasing redness, warmth, swelling, or discharge), severe or worsening pain, or any unexpected skin changes following treatment.

Reporting adverse effects: Suspected adverse incidents involving microneedling devices, or side effects from associated medicines, should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

How to Access Microneedling for Hair Loss in the UK

Microneedling for hair loss is not available on the NHS and must be accessed privately; patients should choose practitioners registered with a statutory regulator such as the GMC, NMC, or GDC, and consult their GP first to identify the underlying cause.

In the UK, microneedling for hair loss is not currently available on the NHS, as it is classified as a cosmetic or aesthetic procedure rather than a medical treatment for which there is sufficient evidence to support routine commissioning. Individuals seeking this treatment will therefore need to access it through private clinics or specialist dermatology practices.

When considering private treatment, it is important to choose a reputable provider. Look for practitioners who:

• Hold relevant qualifications in dermatology, aesthetic medicine, or a related clinical field, and are registered with a statutory regulator such as the GMC, NMC, or GDC

• Practise in a setting that meets appropriate safety and hygiene standards; where the clinic provides regulated activities, it should be registered with the Care Quality Commission (CQC) — however, not all aesthetic clinics fall within CQC-regulated activities, so it is also advisable to check whether the practitioner is listed on an accredited voluntary register such as the Joint Council for Cosmetic Practitioners (JCCP) or Save Face

• Conduct a thorough consultation and scalp assessment before recommending treatment

• Provide clear information about expected outcomes, risks, and the number of sessions likely required

For individuals concerned about hair loss, the recommended first step is to speak with their GP, who can help identify the underlying cause — which may include nutritional deficiencies, thyroid dysfunction, hormonal imbalances, or autoimmune conditions — and refer to an NHS dermatologist if clinically indicated.

Established first-line treatments include topical minoxidil (available from pharmacies without a prescription) and finasteride (prescription-only for men). Both are recognised as evidence-based options by the NHS and the British Association of Dermatologists (BAD). Patients considering finasteride should be aware of the MHRA Drug Safety Update regarding potential sexual dysfunction and psychiatric side effects, and should discuss these with their prescriber before starting treatment.

The cost of private microneedling sessions in the UK typically ranges from £100 to £350 per session, depending on location and whether adjunct treatments such as PRP are included. Multiple sessions are usually required, making it a significant financial commitment. Patients should approach any clinic offering guaranteed results with caution, as no treatment can promise complete hair restoration, and outcomes vary considerably between individuals.

For further information, the NHS hair loss page and BAD patient information leaflets on male and female pattern hair loss, alopecia areata, and skin needling provide reliable, evidence-based guidance.

Frequently Asked Questions